<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE335nnn/GSE335945/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE335945</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Blockage of Ca2+-permeable AMPA receptors suppresses proliferation of schwannoma cells</name><description>Schwannomas are common benign tumors, but management of large or multiple tumors, such as those in NF2-related schwannomatosis, remains challenging due to the risks associated with surgery and radiotherapy. Drug repositioning offers a promising strategy for these slow-growing tumors. While the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is a known therapeutic target in glioma to prevent seizure and growth, its expression and role in schwannoma have not been fully elucidated. We analyzed the intracellular genetic changes induced by PER treatment using RNA-seq. We treated human fibroblast cell lines (TIG-1) and human schwannoma cell lines (YST-1, HS-PSS) with PER at concentrations of 0 μM (control group), 10 μM, and 30 μM, respectively, and performed RNA-seq after culturing the cells for 7 days.</description><dates><publication>2026/06/19</publication></dates><accession>GSE335945</accession><cross_references><GSM>GSM9824080</GSM><GSM>GSM9824081</GSM><GSM>GSM9824079</GSM><GSM>GSM9824075</GSM><GSM>GSM9824076</GSM><GSM>GSM9824077</GSM><GSM>GSM9824078</GSM><GSM>GSM9824082</GSM><GSM>GSM9824083</GSM><GPL>34284</GPL><GSE>335945</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>